Stocks Health care TDOC
NYSE · Health careTeladoc Health, Inc. (TDOC)
Teladoc Health, Inc. brought in $2.5B of revenue over the twelve months to September 30, 2026, down 2.4% from a year earlier. It posted a net loss of $154.8M. Operating cash flow minus capital spending left $285.5M of free cash flow in fiscal 2025. At September 30, 2026 it held $849.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 29, 2026.
Key facts about Teladoc Health, Inc.
- Net worth
- Teladoc Health, Inc. has a market value (market cap) of $1.6B at the latest share price, and shareholders' equity of $1.3B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $2.5B (-1.5% year on year), with a net loss of $200.3M. Over the 12 months to September 30, 2026: revenue $2.5B, net loss $154.8M.
- Cash flow
- In fiscal 2025 operations brought in $294.4M of cash; after $8.9M of capital spending, free cash flow was $285.5M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 29, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Teladoc Health, Inc.'s next report is expected around February 24, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Teladoc Health, Inc. does
Teladoc Health, Inc. is registered with the SEC under industry code SIC 8011 (Services-Offices & Clinics of Doctors of Medicine). Its shares trade on NYSE under the ticker TDOC.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $2.5B | -$200.3M | -$1.14 | $285.5M |
| 2024 | $2.6B | -$1B | -$5.87 | $282.9M |
| 2023 | $2.6B | -$220.4M | -$1.34 | $338.6M |
| 2022 | $2.4B | -$13.7B | -$84.60 | $172.8M |
| 2021 | $2B | -$428.8M | -$2.73 | $185.5M |
| 2020 | $1.1B | -$485.1M | -$5.36 | -$57.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where TDOC ranks in Health care
Latest SEC filings
What Teladoc Health, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 29, 2026Quarterly report 10-Q · period to September 30, 2026Revenue fell 3.4% to $605.1M versus the same quarter last year; diluted EPS -$0.15 versus -$0.28.
- October 28, 2026
- October 8, 2026Passive stake (5% or more) SCHEDULE 13G
- September 25, 2026Executive or director change8-KTeladoc Health announced that Chief Legal Officer Adam C. Vandervoort will resign and Jonathan Dorfman will succeed him.
- August 31, 2026
- August 13, 2026
- August 3, 2026
- July 30, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 4% to $606.9M versus the same quarter last year; diluted EPS -$0.21 versus -$0.19.
- July 29, 2026
- June 22, 2026Passive stake (5% or more) SCHEDULE 13G
What is TDOC worth? A DCF from its reported cash flow
Insider trades
What the people running Teladoc Health, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $731.7K worth of shares in the last 90 days and bought none on the open market. Most of the selling (50%) was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 6, 2026 | Nueno CarlosPresident, International | Soldpre-planned (10b5-1) | 29,432 | $270.8K |
| October 2, 2026 | Catapano Joseph RonaldChief Accounting Officer | Sold | 655 | $3.7K |
| October 1, 2026 | Catapano Joseph RonaldChief Accounting Officer | Exercised options | 2,083 | - |
| September 11, 2026 | Divita Charles IIICHIEF EXECUTIVE OFFICER, Director | Sold | 17,805 | $108.7K |
| September 10, 2026 | Divita Charles IIICHIEF EXECUTIVE OFFICER, Director | Exercised options | 3,642 | - |
| September 10, 2026 | Divita Charles IIICHIEF EXECUTIVE OFFICER, Director | Exercised options | 39,160 | - |
| September 3, 2026 | Rodrigues Fernando M.President of BetterHelp | Soldpre-planned (10b5-1) | 9,812 | $63.9K |
| September 2, 2026 | Divita Charles IIICHIEF EXECUTIVE OFFICER, Director | Sold | 18,327 | $115.5K |
Who owns TDOC
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Vanguard Portfolio Management13G, passive | 6.97% | April 29, 2026 |
| Vanguard Capital Management13G, passive | 5.16% | April 30, 2026 |
| Dimensional Fund Advisors LP13G, passive | 5% | October 8, 2026 |
| Voss Capital, LP13G, passive with 4 related filers | 5% | June 22, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 347 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 16,223,134 | +1,609,578 |
| Vanguard Portfolio Management LLC | 12,685,592 | +390,498 |
| Point72 Asset Management, L.P. | 8,239,927 | +518,432 |
| Renaissance Technologies LLC | 8,072,842 | -12,700 |
| Voss Capital, LP | 8,046,679 | +3,846,679 |
| Vanguard Capital Management LLC | 7,955,032 | +97,863 |
| Dimensional Fund Advisors LP | 7,371,699 | +1,073,294 |
| State Street Corp | 4,962,382 | +602,631 |
| American Century Companies Inc | 4,894,504 | +1,438,120 |
| Allianz Asset Management GmbH | 4,666,596 | -124,767 |
| Geode Capital Management, LLC | 4,653,834 | +473,350 |
| Goldman Sachs Group Inc | 3,822,284 | +1,115,949 |
| Monaco Asset Management SAM | 3,167,979 | -862,177 |
| Jupiter Asset Management Ltd | 3,109,714 | 0 |
| Charles Schwab Investment Management Inc | 3,063,252 | +25,278 |
| Quantinno Capital Management LP | 2,818,917 | +197,539 |
| Federated Hermes, Inc. | 2,127,008 | +422,482 |
| UBS Group AG | 2,052,026 | +325,203 |
| Arrowstreet Capital, Limited Partnership | 2,040,051 | new |
| Ameriprise Financial Inc | 2,004,550 | +188,620 |
Insiders
10 insiders reported holding 985,884 shares in total, about $8.8M at the last price.
| Holder | Shares |
|---|---|
| Divita Charles IIICHIEF EXECUTIVE OFFICER, Director | 465,535 |
| Vandervoort Adam CCHIEF LEGAL OFFICER, SECRETARY | 117,616 |
| Snow David B JrDirector | 113,032 |
| Bliss KellyPresident, U.S. Group Health | 92,832 |
| Jacobson CatherineDirector | 66,853 |
| Shedlarz David LDirector | 61,266 |
| Nueno CarlosPresident, International | 35,312 |
| Catapano Joseph RonaldChief Accounting Officer | 14,293 |
| Paulus Kenneth HDirector | 10,000 |
| Evans Jason EricDirector | 9,145 |
Questions about TDOC
What does Teladoc Health, Inc. do?
Teladoc Health, Inc. is a company in the Health care sector, listed on NYSE as TDOC. Its shares trade on NYSE under the ticker TDOC.
What is Teladoc Health, Inc.'s net worth?
Teladoc Health, Inc. has a market value (market cap) of $1.6B at the latest share price, and shareholders' equity of $1.3B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Teladoc Health, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $154.8M on revenue of $2.5B.
How much revenue does Teladoc Health, Inc. make?
Over the twelve months to September 30, 2026 Teladoc Health, Inc. reported revenue of $2.5B. That is 2.4% less than a year earlier.
When did Teladoc Health, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on October 29, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the insider trade from November 9, 2026.
When is Teladoc Health, Inc.'s next earnings report?
Teladoc Health, Inc.'s next report is expected around February 24, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare TDOC with
Follow TDOC
Get an email when Teladoc Health, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Teladoc Health, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.